Valuation: Grifols, S.A.

Market Cap 5.81B 6.62B 5.4B 4.96B 9.32B 637B 9.46B 64.17B 25.07B 313B 24.84B 24.3B 1,083B P/E 2026 *
12.8x
P/E 2027 * 9.51x
Enterprise Value 14.2B 16.17B 13.21B 12.12B 22.77B 1,557B 23.12B 157B 61.27B 766B 60.7B 59.39B 2,647B EV / Sales 2026 *
1.85x
EV / Sales 2027 * 1.7x
Free-Float
79.65%
Yield 2026 *
2.69%
Yield 2027 * 3.07%
Manager TitleAgeSince
Chief Executive Officer 57 2024-03-31
Director of Finance/CFO 49 2024-09-15
Compliance Officer 54 2013-12-31
Director TitleAgeSince
Chairman 76 2010-01-24
Director/Board Member 70 2000-04-12
Director/Board Member 62 2015-05-23
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+6.30% - - 6.62B
+0.63%-3.06%+16.50%-10.25% 66.74B
+0.08%+3.49%+37.71%+204.60% 53.32B
+10.08%+51.80%+51.80%+51.80% 48.12B
+1.90%-5.07%-56.99%-56.52% 38.25B
+0.78%-1.84%+53.73%-23.77% 29.85B
+0.84%+0.36%+67.62%+87.37% 23.51B
-5.17%-12.54%+58.33%-55.18% 21.45B
+1.31%+3.24%+81.47%+159.24% 16.47B
+0.17%-0.95%+62.74%+124.14% 16.38B
Average +1.07%-0.72%+41.44%+53.49% 34.9B
Weighted average by Cap. +1.75%+0.01%+32.60%+48.94%

Financials

2026 *2027 *
Net sales 7.68B 8.74B 7.14B 6.55B 12.31B 842B 12.5B 84.81B 33.13B 414B 32.82B 32.12B 1,431B 8.15B 9.28B 7.58B 6.96B 13.08B 894B 13.28B 90.06B 35.18B 440B 34.86B 34.1B 1,520B
Net income 513M 584M 477M 438M 823M 56.29B 836M 5.67B 2.21B 27.67B 2.19B 2.15B 95.68B 692M 788M 644M 591M 1.11B 75.87B 1.13B 7.64B 2.99B 37.3B 2.96B 2.89B 129B
Net Debt 8.39B 9.55B 7.8B 7.16B 13.45B 920B 13.66B 92.65B 36.2B 452B 35.86B 35.09B 1,564B 8.08B 9.2B 7.51B 6.89B 12.95B 886B 13.15B 89.22B 34.86B 435B 34.53B 33.79B 1,506B
Logo Grifols, S.A.
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (86.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.5%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.1%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.2%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.6%), European Union (15.9%), the United States and Canada (56.5%) and other (22%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-